10-K/A - HCTI - Equibles

UNITED

STATES

SECURITIES

AND EXCHANGE COMMISSION

Washington,

D.C. 20549

Form

10-K/A

(AmendmentNo. 1)

(Mark One)

☒

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Forthe fiscal year ended December 31, 2022

☐

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For

the Transition Period from to

Commission

File Number: 001-40903

HEALTHCARE TRIANGLE, INC.

(Exact name of registrant as specified in its charter)

Delaware	84-3559776
(State<br> or other jurisdiction of incorporation or organization)	(I.R.S.<br> Employer Identification No.)
7901 Stoneridge Drive, Suite 220 Pleasanton , CA	94588
(Address<br> of principal executive offices)	(Zip<br> Code)
(925) 270-4812
---
(Registrant’s<br> telephone number, including area code)
Securities<br> registered pursuant to Section 12(b) of the Act:
Title of each class	Ticker Symbol(s)	Name of each exchange on which registered
---	---	---
Common<br> Stock, $0.00001 par value	HCTI	The<br> Nasdaq Stock Market LLC
Securities<br> registered pursuant to Section 12(g) of the Act: None

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act.

Yes ☐ No ☒

Indicate by check if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.

Yes ☐ No ☒

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.

Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer”, “accelerated filer”, “smaller reporting company”, and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐	Accelerated filer ☐	Non-accelerated filer ☒	Smaller reporting company ☒	Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. ☐

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. ☐

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to §240.10D-1(b). ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act).

Yes ☐ No ☒

The

aggregate market value of the 1,261,667 shares of Common Stock of the registrant held by non-affiliates on June 30, 2022, based on the price at which the common stock sold on the last business day of the registrant’s second quarter, is $12,995,170.

As

of January 4, 2024, 4,308,822 shares of the registrant’s common stock, $0.00001 par value per share, were issued and outstanding.

| 1 |

| --- |

Explanatory

Note

The purpose of this Amendment No. 1 to the Annual Report on Form 10-K of Healthcare Triangle, Inc. (the “Company”) for the fiscal year ended December 31, 2022, filed with the U.S. Securities and Exchange Commission (the “SEC”) on March 28, 2023 (the “Original Report” and together with this Amendment No. 1, this “Report”), is to amend (i) the cover page of the Original Report with certain required information and (ii) Item 8, Part II of the Original Report to remove the Report of Independent Registered Public Accounting Firm issued by Ram Associates, CPAS (“Ram”), which relates to the consolidated financial statements of the Company for the year ended December 31, 2021 (the “2021 Financial Statements”) and replace it with the Report of Independent Registered Public Accounting Firm issued by BF Borgers CPA PC (PCAOB ID 5041) (“Borgers”), which relates to the 2021 Financial Statements. The Company engaged Borgers to audit the 2021 Financial Statements which had previously been audited by Ram because of certain sanctions imposed on Ram by the Public Company Accounting Oversight Board. No changes to the 2021 Financial Statements resulted from the Borgers audit.

Except as described above and the inclusion of Exhibits 31.1, 31.2, 32.1 and 32.1, this Amendment No. 1 to the Original Report does not amend, update or change any other items or disclosures in the Original Report and does not purport to reflect information or events subsequent to the filing thereof.

The Company has attached to this Amended 10-K updated certifications executed as of the date of this Amended 10-K by the Principal Executive Officer and Principal Financial Officer as required by Sections 302 and 906 of the Sarbanes Oxley Act of 2002. These updated certifications are attached as Exhibits 31.1, 31.2, 32.1 and 32.2 to this Amended 10-K.

| 2 |

| --- |

PART

Item8. Financial Statements and Supplementary Data

Report

of Independent Registered Public Accounting Firm

To the shareholders and the board of directors of Healthcare Triangle, Inc.

Opinionon the Financial Statements

We have audited the accompanying consolidated balance sheets of Healthcare Triangle, Inc. as of December 31, 2022 and 2021, the related statements of operations, stockholders’ equity (deficit), and cash flows for the years then ended, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2022 and 2021, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States.

SubstantialDoubt about the Company’s Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 2 to the financial statements, the Company’s operating losses raise substantial doubt about its ability to continue as a going concern. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basisfor Opinion

These financial statements are the responsibility of the Company’s management. Our responsibility is to express an opinion on the Company’s financial statements based on our audit. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (“PCAOB”) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company’s internal control over financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/S/ BF Borgers CPA PC

BFBorgers CPA PC (PCAOB ID 5041)

We have served as the Company’s auditor since 2023

Lakewood, CO

January 3, 2024

| 4 |

| --- |

PART

Item15. Exhibits, Financial Statement Schedules.

Exhibits. The following exhibits are included herein or incorporated herein by reference:

EXHIBIT

INDEX

Exhibit<br> No.	Description
31.1	Certification<br> of the Chief Executive Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section<br> 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification<br> of the Chief Financial Officer pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934, as adopted pursuant to Section<br> 302 of the Sarbanes-Oxley Act of 2002.
32.1*	Certification<br> of the Chief Executive Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to<br> Section 906 of the Sarbanes-Oxley Act of 2002.
32.2*	Certification of the Chief Financial Officer pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

*Exhibits 32.1 and 32.2 are being furnished and shall not be deemed to be “filed” for purposes of Section 18 of the Exchange Act, or otherwise subject to the liability of that section, nor shall such exhibits be deemed to be incorporated by reference in any registration statement or other document filed under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise specifically stated in such filing.

| 6 |

| --- |

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Healthcare<br> Triangle, Inc.
Date:	January<br> 4, 2024	By:	/s/ Dave Rosa
			Dave<br> Rosa
			Chairman<br> of the Board and Director

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities indicated on January 4, 2024.

Signature	Title
/s/ Dave Rosa	Chairman<br> of the Board Director
Dave<br> Rosa
/s/ Thyagarajan Ramachandran	Chief<br> Financial Officer (principal financial and accounting officer)
Thyagarajan<br> Ramachandran
/s/ Lakshmanan Kannappan	Head<br> of Strategic Partnership and Director (principal executive officer)
Lakshmanan<br> Kannappan
/s/ Shibu Kizhakevilayil	Director
Shibu<br> Kizhakevilayil
/s/ Ronald McClurg	Director
Ronald<br> McClurg
/s/ Jainal Bhuiyan	Director
Jainal<br> Bhuiyan

| 7 |

| --- |

CERTIFICATIONPursuant to Rule 13a-14(a)

I, Lakshmanan Kannappan, certify that:

1.	I have reviewed this Amendment No. 1 on Form 10-K/A of Healthcare Triangle, Inc.; and
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact<br>or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were<br>made, not misleading with respect to the period covered by this report.
---	---
Date: January 4, 2024	By:	/s/ Lakshmanan Kannappan
---	---	---
	Name:	Lakshmanan Kannappan
	Title:	Head of Strategic Partnership
		(Principal Executive Officer)

CERTIFICATIONPursuant to Rule 13a-14(a)

I, Thyagarajan Ramachandran, certify that:

1.	I have reviewed this Amendment No. 1 on Form 10-K/A of Healthcare Triangle, Inc.; and
2.	Based on my knowledge, this report does not contain any untrue statement of a material fact<br>or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were<br>made, not misleading with respect to the period covered by this report.
---	---
Date: January 4, 2024	By:	/s/ Thyagarajan Ramachandran
---	---	---
	Name:	Thyagarajan Ramachandran
	Title:	Chief Financial Officer
		(Principal Financial Officer)

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANTTO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report on Form 10-K of Healthcare Triangle, Inc. (the “Company”) for the period ending December 31, 2022 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to my knowledge:

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities<br>Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial<br>condition and results of operations of the Company.
---	---
Date: January 4, 2024	By:	/s/ Lakshmanan Kannappan
---	---	---
	Name:	Lakshmanan Kannappan
	Title:	Head of Strategic Partnership
		(Principal Executive Officer)

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350, AS ADOPTED PURSUANTTO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

(1)	The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities<br>Exchange Act of 1934; and
(2)	The information contained in the Report fairly presents, in all material respects, the financial<br>condition and results of operations of the Company.
---	---
Date: January 4, 2024	By:	/s/ Thyagarajan Ramachandran
---	---	---
	Name:	Thyagarajan Ramachandran
	Title:	Chief Financial Officer
		(Principal Financial Officer)